ONCOPREX® Nanoparticle Delivery System

Our oncology platform utilizes our non-viral Oncoprex® Nanoparticle Delivery System. Using this system, anti-cancer genes expressing DNA plasmids contained in lipid nanoparticles are delivered intravenously to the patient. This platform, originally developed through collaborative research between the University of Texas MD Anderson Cancer Center and the National Institutes of Health, has been optimized to work with our initial drug candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid).

Designed to Deliver Cancer-Fighting Genes Systemically

REQORSA® utilizes the ONCOPREX® Nanoparticle Delivery System to encapsulate the TUSC2 gene in positively charged nanoparticles that bind to negatively charged cancer cells, and then enter the cancer cell through selective endocytosis, a process by which cells take in substances from outside the cell by engulfing them in a vesicle. The nanoparticles in our system differ significantly from liposomes historically used for drug delivery in that they are true particles encapsulating the therapeutic payload within a bilamellar lipid coat.

Safety and Efficacy

We have administered REQORSA to more than 50 patients in Phase 1 and 2 clinical trials using our systemic, proprietary, ONCOPREX non-viral delivery system.

A Phase 1 clinical trial showed that systemic, intravenous REQORSA therapy using the ONCOPREX Nanoparticle Delivery System selectively and preferentially targeted tumor cells, resulting in clinically significant anticancer activity. The nanoparticles are non-immunogenic, allowing repetitive therapeutic dosing and providing extended half-life in the circulation.

Our earlier clinical trials have also shown that REQORSA therapy using the ONCOPREX Nanoparticle Delivery System is well tolerated in humans and can be delivered at high therapeutic doses. We believe the ONC-001 clinical trial was the first systemic gene therapy clinical trial using a nanoparticle delivery system to deliver a tumor suppressor gene.